BioMarin Pharmaceutical (BMRN) has risen sharply, recording gains of 0.39% in the past 4 weeks. However, the stock has corrected -6.57% in the past 1 week, providing a good buying opportunity on dips. BioMarin Pharmaceutical (BMRN) : During the past 4 weeks, traders have been relatively bearish on BioMarin Pharmaceutical (BMRN), hence the stock is down -0.63% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -6.62% relative to the S&P 500.
The stock has recorded a 20-day Moving Average of 3.38% and the 50-Day Moving Average is 4.56%. BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Friday. Though the stock opened at $91.49, the bulls momentum made the stock top out at $92.49 level for the day. The stock recorded a low of $91.02 and closed the trading day at $92.44, in the green by 0.47%. The total traded volume for the day was 1,346,784. The stock had closed at $92.01 in the previous days trading.
The company Insiders own 2.5% of BioMarin Pharmaceutical shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.39% . During last six month period, the net percent change held by insiders has seen a change of -5.1%. Also, Brokerage firm Barclays maintains its rating on BioMarin Pharmaceutical (NASDAQ:BMRN). As per the latest information, the brokerage house raises the price target to $125 per share from a prior target of $105. The shares have been rated Overweight. The rating by the firm was issued on August 5, 2016.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).